Parenteral Cosmetic cross-reference

Cysteine

CAS 52-90-4

Cysteine (CAS 52-90-4) is a Phase 4 pharmaceutical compound with 1 bioactivity target and 18 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
5
SOURCE DrugCentral
Adverse signals
18
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Cysteine
CAS Number
52-90-4
UNII
K848JZ4886
InChIKey
XUJNEKJLAYXESH-REOHCLBHSA-N
ChEMBL ID
CHEMBL863
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
carbocysteine
natural productparenteral
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL863 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE EMBL-EBI ChEMBL 5 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- AC50 29155.219999999998 nM 30 -
- IC50 35793.23142857143 nM 6 -
- EC50 20000 nM 1 -
- Ki 59000 nM 1 -
Cystine/glutamate transporter
Transporter
Ki 4.23 - Homo sapiens
SOURCE DrugCentral 1 association

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Parenteral nutrition associated liver disease 27 283.754 10074151

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 3 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
CYSTEINE 3024 SU MTHSPL
carbocysteine 2023 IN RXNORM
cysteine 3024 IN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Cysteine used for in pharmaceutical contexts?

Cysteine (CAS 52-90-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Cysteine?

Cysteine has 18 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Parenteral nutrition associated liver disease, Acute myocardial infarction, Antibody test positive, Drug ineffective, Dry mouth. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Cysteine also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for L-Cysteine with EU status "permitted".

What clinical phase is Cysteine in?

Cysteine is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Cysteine?

Cysteine has 5 bioactivity rows in this page query. Rendered target entries include Cystine/glutamate transporter.